select a format

Single User License
USD 3500 INR 224560
Site License
USD 7000 INR 449120
Corporate User License
USD 10500 INR 673680

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Histone Deacetylase 1 EC 3.5.1.98-Pipeline Review, H1 2016

Histone Deacetylase 1 EC 3.5.1.98-Pipeline Review, H1 2016


  • Products Id :- GMDHC0106TDB
  • |
  • Pages: 111
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Histone Deacetylase 1 (EC 3.5.1.98)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Histone Deacetylase 1 (EC 3.5.1.98)-Pipeline Review, H1 2016', provides in depth analysis on Histone Deacetylase 1 (EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 1 (EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (EC 3.5.1.98)

The report reviews Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Histone Deacetylase 1 (EC 3.5.1.98) Overview 9

Therapeutics Development 10

Histone Deacetylase 1 (EC 3.5.1.98)-Products under Development by Stage of Development 10

Histone Deacetylase 1 (EC 3.5.1.98)-Products under Development by Therapy Area 11

Histone Deacetylase 1 (EC 3.5.1.98)-Products under Development by Indication 12

Histone Deacetylase 1 (EC 3.5.1.98)-Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Histone Deacetylase 1 (EC 3.5.1.98)-Products under Development by Companies 17

Histone Deacetylase 1 (EC 3.5.1.98)-Products under Development by Universities/Institutes 23

Histone Deacetylase 1 (EC 3.5.1.98)-Therapeutics Assessment 25

Assessment by Monotherapy/Combination Products 25

Assessment by Mechanism of Action 26

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Histone Deacetylase 1 (EC 3.5.1.98)-Companies Involved in Therapeutics Development 31

4SC AG 31

Acetylon Pharmaceuticals, Inc. 32

Chipscreen Biosciences Ltd 33

Curis, Inc. 34

GlaxoSmithKline Plc 35

HitGen LTD 36

IRBM Science Park SpA 37

Italfarmaco S.p.A. 38

MEI Pharma, Inc. 39

Merck & Co., Inc. 40

Mirati Therapeutics Inc. 41

Oncolys BioPharma Inc. 42

Sigma-Tau S.p.A. 43

Syndax Pharmaceuticals, Inc. 44

TetraLogic Pharmaceuticals 45

Histone Deacetylase 1 (EC 3.5.1.98)-Drug Profiles 46

4SC-202-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

ACY-738-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ACY-957-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

chidamide-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

crocetin-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

CS-3158-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

CUDC-907-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

entinostat-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

givinostat-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

HG-3001-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Largazole-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

mocetinostat-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

N-140-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

OBP-801-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

pracinostat-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

remetinostat-Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Small Molecule to Inhibit Histone Deacetylase 1 for Beta-Thalassemia-Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecule to Inhibit Histone Deacetylases for Oncology-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecules to Inhibit BRD4 and HDAC1 for Oncology-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

ST-3595-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

vorinostat-Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Histone Deacetylase 1 (EC 3.5.1.98)-Dormant Projects 95

Histone Deacetylase 1 (EC 3.5.1.98)-Featured News & Press Releases 99

Jun 05, 2016: Mirati Therapeutics Provides Update On Mocetinostat Program 99

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 99

May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 99

May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One 100

Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 101

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 103

Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 103

Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting 103

Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 104

Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 104

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 105

Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study 105

Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models 106

Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 107

Dec 03, 2015: Syndax Announces Multiple Data Presentations on Entinostat at Upcoming San Antonio Breast Cancer Symposium 109

Appendix 110

Methodology 110

Coverage 110

Secondary Research 110

Primary Research 110

Expert Panel Validation 110

Contact Us 110

Disclaimer 111

List of Figures

Number of Products under Development for, H1 2016 10

Number of Products under Development by Therapy Area, H1 2016 11

Number of Products under Development by Top 10 Indication, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 15

Comparative Analysis by Early Stage Products, H1 2016 16

Assessment by Monotherapy/Combination Products, H1 2016 25

Number of Products by Stage and Mechanism of Actions, H1 2016 26

Number of Products by Routes of Administration, H1 2016 27

Number of Products by Stage and Routes of Administration, H1 2016 27

Number of Products by Molecule Types, H1 2016 29

Number of Products by Stage and Molecule Type, H1 2016 29

List of Tables

Number of Products under Development for, H1 2016 10

Number of Products under Development by Therapy Area, H1 2016 11

Number of Products under Development by Indication, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 15

Comparative Analysis by Early Stage Products, H1 2016 16

Number of Products under Development by Companies, H1 2016 17

Products under Development by Companies, H1 2016 18

Products under Development by Companies, H1 2016 (Contd..1) 19

Products under Development by Companies, H1 2016 (Contd..2) 20

Products under Development by Companies, H1 2016 (Contd..3) 21

Products under Development by Companies, H1 2016 (Contd..4) 22

Number of Products under Investigation by Universities/Institutes, H1 2016 23

Products under Investigation by Universities/Institutes, H1 2016 24

Assessment by Monotherapy/Combination Products, H1 2016 25

Number of Products by Stage and Mechanism of Action, H1 2016 26

Number of Products by Stage and Route of Administration, H1 2016 28

Number of Products by Stage and Molecule Type, H1 2016 30

Pipeline by 4SC AG, H1 2016 31

Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 32

Pipeline by Chipscreen Biosciences Ltd, H1 2016 33

Pipeline by Curis, Inc., H1 2016 34

Pipeline by GlaxoSmithKline Plc, H1 2016 35

Pipeline by HitGen LTD, H1 2016 36

Pipeline by IRBM Science Park SpA, H1 2016 37

Pipeline by Italfarmaco S.p.A., H1 2016 38

Pipeline by MEI Pharma, Inc., H1 2016 39

Pipeline by Merck & Co., Inc., H1 2016 40

Pipeline by Mirati Therapeutics Inc., H1 2016 41

Pipeline by Oncolys BioPharma Inc., H1 2016 42

Pipeline by Sigma-Tau S.p.A., H1 2016 43

Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 44

Pipeline by TetraLogic Pharmaceuticals, H1 2016 45

Dormant Projects, H1 2016 95

Dormant Projects (Contd..1), H1 2016 96

Dormant Projects (Contd..2), H1 2016 97

Dormant Projects (Contd..3), H1 2016 98

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

Acetylon Pharmaceuticals, Inc.

Chipscreen Biosciences Ltd

Curis, Inc.

GlaxoSmithKline Plc

HitGen LTD

IRBM Science Park SpA

Italfarmaco S.p.A.

MEI Pharma, Inc.

Merck & Co., Inc.

Mirati Therapeutics Inc.

Oncolys BioPharma Inc.

Sigma-Tau S.p.A.

Syndax Pharmaceuticals, Inc.

TetraLogic Pharmaceuticals

Histone Deacetylase 1 (EC 3.5.1.98) Therapeutic Products under Development, Key Players in Histone Deacetylase 1 (EC 3.5.1.98) Therapeutics, Histone Deacetylase 1 (EC 3.5.1.98) Pipeline Overview, Histone Deacetylase 1 (EC 3.5.1.98) Pipeline, Histone Deacetylase 1 (EC 3.5.1.98) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com